Search

Author/Creator Britten, C.D.

1. 2630 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic urothelial carcinoma: A phase Ib trial. (September 2015)

Authors:
Apolo, A.B.; Infante, J.R.; Hamid, O.; Patel, M.; Wang, D.; Kelly, K.; Mega, A.; Britten, C.D.; Mita, A.; Ravaud, A.; Cuillerot, J.M.; Von Heydebreck, A.; Gulley, J.L.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S522
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors. (December 2016)

Authors:
Razak, A.; Gore, L.; Britten, C.D.; Miller, W.H.; Uy, G.L.; Nichols, G.; Middleton, S.; Blotner, S.; Zhi, J.; Jukofsky, L.; Pierceall, W.; Higgins, B.; Chen, L.C.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S21
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search